Amgen Inc. just missed some Wall Street targets for the quarter and the year but overall rode through 2008 well after undergoing a major restructuring in 2007. The company faces further challenges for what was once its top drug even as it prepares to bring a potential blockbuster drug to market. For the full story click here
